Arbutus Biopharma (NASDAQ:ABUS)‘s stock had its “buy” rating reaffirmed by research analysts at Chardan Capital in a research report issued on Tuesday.
A number of other equities analysts have also recently commented on the company. Zacks Investment Research cut Arbutus Biopharma from a “hold” rating to a “sell” rating in a report on Thursday. B. Riley started coverage on Arbutus Biopharma in a report on Friday, January 5th. They issued a “buy” rating and a $10.00 target price for the company. BidaskClub raised Arbutus Biopharma from a “sell” rating to a “hold” rating in a report on Thursday, January 4th. ValuEngine cut Arbutus Biopharma from a “sell” rating to a “strong sell” rating in a report on Friday, December 15th. Finally, Leerink Swann reaffirmed a “market perform” rating and issued a $5.00 target price (up previously from $4.00) on shares of Arbutus Biopharma in a report on Tuesday, November 7th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. Arbutus Biopharma currently has an average rating of “Hold” and an average price target of $12.50.
Arbutus Biopharma (NASDAQ:ABUS) opened at $5.20 on Tuesday. The company has a current ratio of 11.03, a quick ratio of 11.03 and a debt-to-equity ratio of 0.08. Arbutus Biopharma has a fifty-two week low of $2.35 and a fifty-two week high of $8.25. The company has a market capitalization of $286.27, a price-to-earnings ratio of -1.05 and a beta of 1.08.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. grew its position in shares of Arbutus Biopharma by 2.7% in the 2nd quarter. Vanguard Group Inc. now owns 77,413 shares of the biopharmaceutical company’s stock valued at $279,000 after buying an additional 2,035 shares during the last quarter. OxFORD Asset Management LLP grew its position in shares of Arbutus Biopharma by 89.9% in the 2nd quarter. OxFORD Asset Management LLP now owns 83,310 shares of the biopharmaceutical company’s stock valued at $300,000 after buying an additional 39,436 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Arbutus Biopharma in the 3rd quarter valued at about $1,393,000. Finally, RTW Investments LP grew its position in shares of Arbutus Biopharma by 1.1% in the 3rd quarter. RTW Investments LP now owns 5,266,280 shares of the biopharmaceutical company’s stock valued at $32,651,000 after buying an additional 56,457 shares during the last quarter. 59.97% of the stock is owned by institutional investors and hedge funds.
Arbutus Biopharma Company Profile
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.